Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Phage Therapy Shown to Kill Drug-Resistant Superbug

By University of Liverpool | March 13, 2017

Scientists from the University of Liverpool’s Institute of Infection and Global Health have shown that phage therapy could offer a safe and effective alternative to antibitotics in the treatment of Cystic Fibrosis lung infections.

Chronic lung infections caused by the bacterium Pseudomonas aeruginosa are becoming increasingly difficult to treat due to antimicrobial resistance (AMR). With limited alternative therapeutic options available this has led to a renewed interest in (bacterio)phage therapy.

Phages are viruses that kill bacteria but are otherwise harmless. A major advantage is that phages only target the harmful bacteria, so there are less side of the effects often associated with antibiotics. Phage therapy however has not had the same level of funding as drug development, due to a lack of convincing pre-clinical efficacy studies.

Here for the first time, researchers have shown that phage therapy is highly effective in treating established and recalcitrant chronic respiratory tract infections caused by multi-drug resistant Pseudomonas aeruginosa strains. They show that phages are capable of killing the bacteria in long term infected lungs, such as those suffered by patients with the inherited disease Cystic Fibrosis, indicating a potential new therapeutic option for these hard to treat life threatening infections.

Professor Aras Kadioglu, who led the study, said: “Given the increasing problems caused by bacteria that are resistant to treatment with antibiotics, there is an urgent need to develop new approaches.  We have shown that phage therapy has the potential to offer a safe and effective alternative for the treatment of such persistent bacterial infections.”

Professor Craig Winstanley, who co-led the study, added: “Cystic Fibrosis patients face the prospect of life-long treatment with antibiotics, which often prove ineffective and can have side effects, especially when used for long periods.  Hence phage therapy could be a particularly valuable addition to the treatment of chronic lung infections in these patients.”

The recent UK Government Review on Antimicrobial Resistance by Jim O’Neil, highlights phage therapy as a potential alternative to antibiotics in the treatment of AMR infections. In addition, the WHO recently identified Pseudomonas aeruginosa as one of the key pathogens against which there is a critical need to develop new therapies. This new study provides valuable pre-clinical evidence for phage therapy being a viable option.

Related Articles Read More >

New dangers in the woods — and the hope that research offers us
Novel mass spectrometry solution simplifies insight gathering into macromolecular complexes
ENPICOM launches display solution to accelerate antibody selection while maximizing precision
Thermo Fisher Scientific autoimmune-testing instruments now available in the U.S.
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars